JTCC Announces Positive Results with New Targeted Biological in Indolent Non-Hodgkin Lymphoma
Andre Goy, M.D., Chairman and Director of John Theurer Cancer Center, Chief of the Lymphoma Program and Chief Science Officer
HIPAA Alert: Potential Data Breach Learn More
Questions on Oncology, Hematology and/or Infusion Clinical Services due to COVID-19 Crisis – CALL 833-698-1623
Important Information for Our Patients Regarding the Coronavirus.
RCCA Providing Area Cancer Patients with Access to Care During Coronavirus Outbreak
RCCA Offering Patients Virtual Visits During Coronavirus Pandemic
We’re here for you. Call us at 844-346-7222 or
Andre Goy, M.D., Chairman and Director of John Theurer Cancer Center, Chief of the Lymphoma Program and Chief Science Officer
Underscoring their commitment to accelerate and contribute to new targeted treatments for blood cancers, Regional Cancer Care Associates (RCCA) researchers/physicians
ndre Goy, M.D., Chairman and Director, and Chief of Lymphoma, John Theurer Cancer Center and Chief Science Officer and Director
ALEXANDRIA, Va. – The American Society of Clinical Oncology (ASCO) has announced its inaugural class of 15 oncology practices and
HACKENSACK, N.J., July 3, 2013 /PRNewswire/ -- Members of Regional Cancer Care Associates (RCCA), one of the nation's largest Oncology
SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG) today announced the U.S. Food and Drug Administration (FDA) has approved the company’s supplemental
Regional Cancer Care Associates’ President Dr. Andrew Pecora Speaks at International Vatican Stem Cell Conference Dr. Pecora Discussed Research and
Is it Time for a New Direction in Oncology Care?
In case you missed it, two new drugs for multiple myeloma have been approved and are expected to extend life
For more information or to schedule an appointment, call (844) 346-7222. You can also schedule an appointment by calling the RCCA location nearest you.
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.